Skip to content

Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy

Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01171027
Enrollment
200
Registered
2010-07-28
Start date
2010-07-31
Completion date
2012-09-30
Last updated
2011-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gall Bladder Diseases

Keywords

Cholecystectomy, NOTES, Transvaginal, Transgastric, Natural orifice, Gallbladder removal

Brief summary

This study is designed to be a United States multicenter prospective randomized controlled non-inferiority evaluation of transgastric and transvaginal Natural Orifice Translumenal Endoscopic Surgery (NOTES) cholecystectomy compared to laparoscopic cholecystectomy in elective surgery patients. Up to 200 patients will be enrolled to obtain 70 NOTES cholecystectomies (35 transgastric and 35 transvaginal) and 70 laparoscopic cholecystectomies on a randomized basis. In order to evaluate the hypothesis that NOTES cholecystectomy has equivalent safety and efficacy to laparoscopic cholecystectomy, clinical and administrative outcomes will be measured.

Detailed description

Primary To assess the safety and efficacy of transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy. To assess pain associated with transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy. Secondary To assess cosmesis associated with transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy. To assess objective operative cost and logistical comparisons between transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy. To identify unforeseen barriers to transgastric or transvaginal surgery adoption.

Interventions

PROCEDURENOTES Cholecystectomy

The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.

PROCEDURELaparoscopic Cholecystectomy

This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.

Sponsors

American Society for Gastrointestinal Endoscopy
CollaboratorOTHER
Natural Orifice Surgery Consortium for Assessment and Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Competent male or female subjects, between the ages of 18-75 and who present for elective cholecystectomy will be offered participation in this study. * Male subjects must be willing to have the cholecystectomy by either the laparoscopic or transgastric NOTES approach. * Female subjects must be willing to have the cholecystectomy by either the laparoscopic or either the NOTES approaches (transgastric and/or transvaginal) being performed at the site. * Patients offered participation in this study must provide written, informed consent and meet the following criteria prior to randomization. * Diagnosis of benign gallstone disease which requires cholecystectomy. * ASA Class 1 or 2. * Willingness to have laparoscopic cholecystectomy performed and have research data collected for control group. * Willingness to have abdomen photographed (for cosmesis assessment). * For sites performing transgastric NOTES approach * Willingness to have cholecystectomy performed via NOTES transgastric approach. * Willingness to have NOTES procedure videotaped. * For sites performing transvaginal NOTES approach - Female subjects only * Willingness to have cholecystectomy performed via NOTES transvaginal approach. * Willingness to have intra-abdominal procedure digitally recorded. * Pelvic examination in the past 12 months without significant pathology.

Exclusion criteria

* Pregnant women. * Obese patients (BMI \> 35). * Patients with severe medical comorbidities (ie, NOT ASA Class 1 or 2) will be excluded such as: * Chronic renal failure * Chronic liver disease * Congestive heart failure * Patients with a presumed gallbladder malignancy. * Patients with a history of prior open abdominal or laparoscopic or transvaginal surgery. However patients with prior appendectomy, tubal ligation or Cesarean section will be included. * Patients who are taking immunosuppressive medications and/or immunocompromised. * Patients with a prior history of perineal trauma leading to significant alteration of vaginal anatomy. * Patients with a history of ectopic pregnancy, pelvic inflammatory disease, large fibroids or severe endometriosis. * Patients with known common bile duct stones. (ie, not cleared prior to surgery). Patients with common bile duct stones discovered intra-operatively will remain in the study. * Patients on anticoagulation drugs other than once daily aspirin. Abnormal blood coagulation tests. Minimal abnormalities may be allowed at the discretion of site principal investigator. * Gallstones\> 2.5cm in diameter. * Presence of untreated esophageal stricture. * Surgically altered gastric anatomy or severe uncorrected paraesophageal types 2, 3 or 4. * Unwillingness to consent to NOTES procedure(s). * Acute cholecystitis or cholangitis * For sites performing transgastric NOTES approach * Contraindicated for esophagogastroduodenoscopy (EGD). * Patients with hypersecretory states.

Design outcomes

Primary

MeasureTime frame
To assess the safety and efficacy of transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.4 weeks post surgery

Secondary

MeasureTime frame
To assess pain associated with transgastric and transvaginal cholecystectomy compared to conventional laparoscopic cholecystectomy.4 weeks post surgery

Countries

United States

Contacts

Primary ContactMichael Kochman, MD
michael.kochman@uphs.upenn.edu215 662 4279
Backup ContactSteven L Schwaitzberg, MD
sschwaitzberg@challiance.org617 665 3193

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026